Diabetes
Refine Search
Pharmaceutical
Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined, according to the firm’s UK marketing director Chris Boulton. Speaking to The Pharma Letter at the impressive AstraZeneca stand at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting in Vienna last week, Mr Boulton said that AstraZeneca is fighting to be at the forefront of the global race to treat diabetes. 29 September 2014
Pharmaceutical
Some 15 new medicines have been recommended for approval at the September meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). 26 September 2014
Pharmaceutical
UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to basal insulin glargine and metformin can achieve similar glycemic control, and reduction in weight, compared to treatment with bolus insulin lispro added to basal insulin glargine and metformin in adult patients with type 2 diabetes. 24 September 2014
Pharmaceutical
Here's our take on the week's top stories. 19 September 2014
Pharmaceutical
The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent on diabetes. Danish diabetes care giant Novo Nordisk is leading the fight against this growing burden, with a number of revolutionary treatments against the disease. The company presented highlights from its diabetes portfolio at a briefing at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, this week. 19 September 2014
Biosimilars
As physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs, new research suggests. 19 September 2014
Pharmaceutical
The US Food and Drug Administration yesterday approved pharma major Eli Lilly’s Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. 19 September 2014
Pharmaceutical
US pharma giant Merck & Co has announced the presentation of the first data from the Phase III clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. 18 September 2014
Biotechnology
Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian pharma major Lupin as part of the drugmaker’s expansion in to emerging markets. 17 September 2014
Pharmaceutical
Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) taking place in Vienna, Austria. 16 September 2014
Generics
US generic drugs major Mylan says it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's Advair Diskus (salmeterol and fluticasone propionate combination) and its insulin analog to Sanofi's Lantus (insulin glargine). 16 September 2014
Pharmaceutical
Family-owned German pharma major Boehringer Ingelheim and US partner Eli Lilly have presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with type 2 diabetes (T2D) already taking metformin and in those who were previously untreated. 16 September 2014
Biosimilars
The European Commission granted marketing authorization for US drug major Eli Lilly and family-owned German pharma company Boehringer Ingelheim’s insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged two years and above. 10 September 2014
Pharmaceutical
The US Food and Drug Administration has published briefing documents on Danish insulin giant Novo Nordisk’s Saxenda for the treatment of obesity ahead of its Advisory Committee Meeting on September 11. 9 September 2014
Biotechnology
Shares of Hyperion Therapeutics’ plunged 11% to $24.61 in pre-market trading today, after the company announced it is terminating development of DiaPep277 for newly diagnosed type 1 diabetes. 8 September 2014
Pharmaceutical
US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes candidate basal insulin peglispro (BIL) compared with French peer Sanofi’s blockbuster Lantus (insulin glargine), which generated $7.6 billion in sales last year, but is due to start losing patent protection next year. 4 September 2014
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced that Mexico has become the first country in the world to launch Ryzodeg, making the drug available for people with type 2 diabetes. 1 September 2014
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their attempt to overturn a combined $9 billion punitive damage award by a US jury for hiding cancer risks associated with their diabetes drug Actos (pioglitazone), according to a court ruling last week. 31 August 2014
Pharmaceutical
In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has called for more evidence on type 2 diabetes drug Jardiance (empagliflozin), produced by German family-owned drug major Boehringer Ingelheim and partner Eli Lilly. 28 August 2014
Biotechnology
Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson. 22 August 2014
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze